Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Seponering av somatostatinanaloger etter PRRT i nevroendokrine svulster i midten av tarmen (STOPNET)

9. november 2026 oppdatert av: Australasian Gastro-Intestinal Trials Group

En randomisert studie av seponering av somatostatinanaloger etter peptidreseptorradionuklidterapi i nevroendokrine svulster i midten av tarmen (STOPNET)

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not.

The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Neuroendocrine tumours commonly originate from the gut and metastasise widely including to the liver, lymph nodes and bones. Originally called "carcinoid tumours", these cancers are most commonly treated with somatostatin analogues (SSA) first line. These analogues treat carcinoid syndrome and slow tumour growth. Despite SSA therapy, progression develops over time. Upon progression, peptide receptor radionuclide therapy (PRRT) is the next standard therapeutic option. After PRRT is initiated, it is unclear if continuing SSA injections is beneficial. There are reasons to believe it might be necessary to continue SSAs, but other reasons to believe they should cease. Given that SSA injections are expensive and associated with side effects, this study aims to clarify the utility of continuing SSA injections after progression on SSA therapy and commencement of PRRT.

STOPNET aims to explore outcomes in grade 1 and 2 mid, hind gut or pancreatic neuroendocrine tumours, that have progressed on SSA therapy, are eligible to receive PRRT and in whom the SSA is either continued or ceased after PRRT is commenced.

The two primary objectives include

  1. To estimate the 20-month progression free survival rate after PRRT commencement in patients who cease and who continue SSA.

  2. Feasibility as measured by:

    1. Recruitment rate and
    2. Patient acceptance of ceasing and staying off SSA over the 20 month follow up period.

The study design of STOPNET is prospective, randomised, non-comparative, open label, multicentre phase II study. Patients meeting the inclusion and exclusion criteria will be randomised, prior to commencing PRRT, to either continue or cease SSA treatment. Randomisation will occur centrally in REDCap by the AGITG STOPNET study team. Randomisation will be 2:1 (the majority being randomised to cease SSA) and will be stratified by WHO tumour grade (1 V 2), sites of metastases (visceral only verse visceral and bone) and institution.

Studietype

Intervensjonell

Registrering (Antatt)

78

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • New South Wales
      • Sydney, New South Wales, Australia, 2065
      • Wollongong, New South Wales, Australia, 2502
    • Queensland
      • Brisbane, Queensland, Australia, 4006
      • Cairns, Queensland, Australia, 4870
      • Toowoomba, Queensland, Australia, 4350
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Rekruttering
        • The Queen Elizabeth Hospital
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Prof Timothy Price
    • Victoria
      • Melbourne, Victoria, Australia, 3000
        • Rekruttering
        • Peter MacCallum Cancer Centre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr Hui-Li Wong
        • Ta kontakt med:
    • Western Australia
      • Kalgoorlie-Boulder, Western Australia, Australia, 6430
      • Perth, Western Australia, Australia, 6150
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Rekruttering
        • Cross Cancer Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr Stella Koumna
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • Rekruttering
        • London Health Sciences Centre Research Institute (LHSCRI)
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr David Laidley
      • Ottawa, Ontario, Canada, K1Y 1J8
        • Rekruttering
        • Ottawa Hospital Research Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr Rachel Goodwin
      • Toronto, Ontario, Canada, M5G 2M9
        • Rekruttering
        • University Health Network Princess Margaret Cancer Centre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr Raymond Jang
      • Toronto, Ontario, Canada, TG 260
        • Rekruttering
        • Odette Cancer Centre Sunnybrook Health Sciences Centre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr Sten Myrehaug
    • Saskatchewan
      • Regina, Saskatchewan, Canada, S4T 7T1
        • Rekruttering
        • Allan Blair Cancer Centre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr Mussawar Iqbal
      • Saskatoon, Saskatchewan, Canada, S7N 4H
        • Rekruttering
        • Saskatoon Cancer Centre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dr Mita Manna

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Adults over 18 years of age with well or moderately differentiated mid or hindgut neuroendocrine tumour, or pancreatic neuroendocrine tumour; metastatic and inoperable, demonstrating progression despite SSA treatment of sufficient disease magnitude to warrant PRRT as determined by the treating clinician and/or the NET Multidisciplinary Team (MDT). See section 4.1 regarding the recording of the reason(s).

  2. Must have measurable disease on triphasic CT/MRI as per RECIST 1.1.

  3. Ki67 ≤20% AND mitotic count ≤20 per HPF (i.e., WHO grade 1 or 2).

    • Note: Participants are eligible if only a single proliferation index has been performed due to local institutional practice, provided that the results are consistent with WHO grade 1 or 2 NET. However, if the results for both Ki67 and mitotic count are available, both results will need to be reported and are subject to eligibility assessment.

  4. Non-functioning NET: SSA treatment will have been commenced for control of tumour growth and not for carcinoid or other hormone overproduction syndrome, as judged by the clinician and/or NET MDT. Non-functioning NET is judged by the treating clinical team based on patient symptomatology.

    In addition, for this study, non-functioning tumour is defined as:

    • Never had escalation of the SSA treatment dose to control carcinoid or other hormone-related symptoms.

    • Never required short acting SSA treatment to control carcinoid or other hormone-related symptoms.

    • For mid and hind gut (GI cohort) patients:

      • 24-hour urine 5-hydroxyindoleacetic acid (5HIAA) <3x upper limit of normal.
      • No significant carcinoid induced valvular heart disease. I.e. Echocardiogram to be within 12 weeks of study randomisation, and deemed safe to proceed with PRRT by the treating team.
    • Note: routine measurement of gastrin, insulin, C-peptide levels, glucagon etc. is not required unless clinically indicated.

  5. Patient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study enrolment, for example a minimum of 30mg Octreotide or 120mg Lanreotide monthly. However, other SSA formulations used at growth-controlling doses are also eligible.

  6. Uptake on SSTR PET scan demonstrating somatostatin receptor expression that is suitable for PRRT as judged by the clinical team. FDG PET scans are to be done at the judgement of the treating team and are not required for enrolment into this study.

  7. PRRT is deemed the most appropriate next treatment step (i.e., patient is inoperable, and liver directed therapies are not preferred).

  8. ECOG performance status 0-2.

  9. Written informed consent. Patients must be willing to either cease or continue SSA, depending on which study arm they are randomised to. Patients must be willing to comply with all other study requirements.

  10. Adequate renal, hepatic and haematologic function as judged by the treating team.

  11. Life expectancy of at least 12 months.

Exclusion Criteria:

  1. This study is for pancreatic, mid-gut and hind-gut NET only. Gastric and lung NETs are excluded.
  2. Any patient on an SSA dose lower than the standard growth-control dose. Patients must have been on an SSA equivalent to Octreotide 30mg or Lanreotide 120mg for at least 3 months prior to study enrolment.
  3. Prior chemotherapy or targeted therapy (e.g., everolimus). Patients who have received prior local therapy, including external beam radiotherapy and liver directed therapy prior to or during SSA therapy are eligible.
  4. Any contraindication to PRRT, as per local institutional practice.
  5. Pregnancy. For female patients of childbearing potential and male patients with a female partner who is of childbearing potential, contraception and counselling is required.
  6. Prior PRRT. Patients being considered for re-treatment with PRRT are not eligible.
  7. Uncontrolled central nervous system metastases. Patients must have completed any surgery or radiation at least 4 weeks prior to enrolment and must be off corticosteroids for at least 2 weeks.
  8. Any patient, in the opinion of the investigator, who will not comply with study assessments and follow up visits. These might include any social, psychological, or geographical concerns, including alcohol/drug abuse.
  9. Any poorly controlled concurrent medical illness that may prevent the patient from complying with study assessments and follow up. This is to be judged by the treating team.
  10. Any concurrent or prior malignancy that, in the opinion of the treating team, may interfere with study assessments and endpoints.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Continue SSA

Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.

Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.

Andre navn:
  • SSA fortsettelse
Eksperimentell: Cease SSA

Patients randomised to cease SSA will receive SSA injection ≥28 days prior to their first cycle of PRRT. Patients will not receive any further long acting SSA injections after this time.

Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.

Andre navn:
  • SSA opphør

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
20-month progression free survival rate after PRRT
Tidsramme: 20 months

Estimate the 20-month progression free survival rate after PRRT in patients who cease and who continue SSA.

20 months
Assess the barriers which would impede the feasibility of a subsequent phase 3 trial
Tidsramme: 20 months
  1. Proportion of participants that remained on the SSA cessation arm for the duration of the 20-month study follow up (patient acceptance of SSA cessation).
  2. Rate of recruitment: ability to complete recruitment over the 24-month recruitment period
20 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Measure Quality of life using the European Organisation For Research And Treatment Of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30) scales
Tidsramme: 20 months

Responses to the QLQ-C30 scale from 0-100 using EORTC guidelines, with higher scores reflecting better level of functioning.

20 months
Measure Quality of life using the EORTC QLQ-GINET21 scales
Tidsramme: 20 months

Responses to the QLQ-GINET21 scale from 0-100 using EORTC guidelines, with higher scores reflecting more severe symptoms.

20 months
Cost-effectiveness of SSA therapy cessation
Tidsramme: The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.

Access to Medicare and PBS data to asses use of other healthcare providers, diagnostic tests and imaging services funded via public health care systems and use of pharmaceutical services respectively.

The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.
Psycho-oncological impacts of SSA therapy cessation: Decision Regret
Tidsramme: 20 months

Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of Decision Regret Scale from 1 - 5 (1-Strongly Agree, 2-Agree, 3-Neither Agree Nor Disagree, 4-Disagree, 5-Strongly Disagree)

20 months
Psycho-oncological impacts of SSA therapy cessation: Fear of Cancer Progression
Tidsramme: 20 months

Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Fear of Cancer Progression Scale from 1 - 5 (1-Never, 2-Seldom, 3-Sometimes, 4-Often, 5-Very often)

20 months
Psycho-oncological impacts of SSA therapy cessation: Decisional Conflict
Tidsramme: 20 months

Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Decisional Conflict Scale from 0 - 4 (0-Strongly Agree, 1-Agree, 2-Neither Agree Nor Disagree, 3-Disagree, 4-Strongly Disagree)

20 months
Time to commencement of subsequent therapy
Tidsramme: 20 months

Time to commencement of subsequent therapy (e.g re-challenge with PRRT, liver directed therapies, chemotherapy, targeted therapies)

20 months
Overall survival
Tidsramme: 20 months

Estimate the 20-month overall survival rate in patients who cease and who continue SSA.

20 months
Rates of SSA being recommenced over time
Tidsramme: 20 months

Cumulative percentage of SSA recommencement over time.

20 months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Exploratory analyses
Tidsramme: 20 months

Exploratory analyses including, but not limited to: Define and validate NET tissue and circulating biomarkers with a particular focus on miRNA.

20 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

14. oktober 2024

Primær fullføring (Antatt)

1. september 2027

Studiet fullført (Antatt)

1. juni 2028

Datoer for studieregistrering

Først innsendt

14. mars 2024

Først innsendt som oppfylte QC-kriteriene

1. april 2024

Først lagt ut (Faktiske)

3. april 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • AG0219NET

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .